WO2021067917A1 - Treatment of eosinophilic disorders with avapritinib - Google Patents

Treatment of eosinophilic disorders with avapritinib Download PDF

Info

Publication number
WO2021067917A1
WO2021067917A1 PCT/US2020/054221 US2020054221W WO2021067917A1 WO 2021067917 A1 WO2021067917 A1 WO 2021067917A1 US 2020054221 W US2020054221 W US 2020054221W WO 2021067917 A1 WO2021067917 A1 WO 2021067917A1
Authority
WO
WIPO (PCT)
Prior art keywords
eosinophilic
compound
pharmaceutically acceptable
eosinophils
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/054221
Other languages
English (en)
French (fr)
Inventor
Brenton MAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Priority to EP20797912.1A priority Critical patent/EP4041244B1/en
Priority to JP2022520638A priority patent/JP2022551105A/ja
Priority to CN202080081643.7A priority patent/CN114746096A/zh
Priority to US17/766,200 priority patent/US20240075041A1/en
Publication of WO2021067917A1 publication Critical patent/WO2021067917A1/en
Anticipated expiration legal-status Critical
Priority to JP2025135336A priority patent/JP2025169361A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Eosinophils are bone marrow-derived granulocytes implicated beneficially in host defense against infection, in anti-tumor cytotoxicity, and in wound healing. Eosinophils are implicated in various diseases including allergic diseases and are thought to play an important role in generating morbidity of allergic diseases, such as chronic bronchial asthma and atopic dermatitis (Adv. Immunol., 39, 177 (1986), Immunol. Today, 13, 501 (1992)).
  • eosinophils are also implicated in diseases generally referred to as hypereosinophilic syndrome (HES), eosinophilia, eosinophilic enterogastritis, eosinophilic leukemia, eosinophilic granuloma and Kimura's disease (Ann. Intern. Med., 97, 78 (1982)).
  • HES hypereosinophilic syndrome
  • eosinophilia eosinophilic enterogastritis
  • eosinophilic leukemia eosinophilic granuloma
  • Kimura's disease Kimura's disease
  • Eosinophils are divided into subgroups, normodense eosinophils and hypodense eosinophils. Eosinophils have been shown to be hypodense eosinophils upon activation (Immunology, 47, 531 (1982)). Hypodense eosinophils are also referred to as activated eosinophils. It has been reported that a qualitative change occurs in addition to a quantitative change in eosinophils in the peripheral blood of an HES patients (Clin. Exp. Immunol., 24, 423 (1976)). Activated eosinophils have been implicated in the severity of HES symptom (Am. J. Cardiol., 52, 321 (1983)).
  • activated eosinophils have been also found in the peripheral blood, and in broncho alveolar lavage fluid (BALE) of patients with bronchial asthma (Am. Rev. Respir. Dis, 132, 981 (1985)).
  • BALE broncho alveolar lavage fluid
  • Various receptors such as those of cytokines, are expressed on activated eosinophils (hypodense eosinophils) (J. Immunol., 142, 4416 (1989)).
  • these hypodense eosinophils show elevated sensitivities against IL-5 (Clin. Exp. Immunol., 85, 312 (1991); J. Exp. Med., 172, 1347 (1990)).
  • treatment for patients with eosinophilic diseases consists of administration of steroids.
  • steroid administration is often associated with side effects.
  • the treatment has some other problems, such that patient's pathological condition may return to the original state when steroid administration is discontinued, and prolonged steroid administration may induce steroid resistance. Accordingly, there is a need for safe and effective treatments for eosinophil related disorders.
  • One aspect of the present disclosure is a method of treating an eosinophilic disorder, comprising administering to a subject in need thereof a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present disclosure is the use of Compound (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating an eosinophilic disorder.
  • Another aspect of the present disclosure is Compound (I) or a pharmaceutically acceptable salt thereof for treating an eosinophilic disorder.
  • Figure 1 shows the absolute eosinophil changes from baseline levels for C1D15 (cycle 1 day 15) in adult patients treated with Compound (I) in a Phase 1 clinical trial after 2 weeks.
  • the dose range of Compound (I) is between 30 mg and 400 mg.
  • Figure 2 shows the absolute eosinophil changes from baseline levels for C1D15 (cycle 1 day 15) in adult patients with KIT allele fraction ⁇ 10% treated with Compound (I) in a Phase 1 clinical trial after 2 weeks.
  • the dose range of Compound (I) is between 30 mg and 400 mg.
  • Figure 3 shows the absolute eosinophil changes from baseline levels for C1D15 (cycle 1 day 15) in adult patients with KIT allele fraction between 10% and 40% treated with Compound (I) (with a dose of 300 mg) in a Phase 1 clinical trial after 2 weeks.
  • Figure 4 shows the absolute eosinophil changes from baseline levels for C1D15 (cycle 1 day 15) in adult patients with KIT allele fraction > 40% treated with Compound (I) in a Phase 1 clinical trial after 2 weeks.
  • the dose range of Compound (I) is between 200 mg and 300 mg.
  • Eosinophils have been implicated in the pathogenesis of numerous diseases and disorders. Eosinophils are a type of white blood cell, which help fight off infections and play a role in body's immune response. They are a normal cellular component of the blood and also of certain tissues, including spleen, lymph nodes, thymus, and the submucosal areas of the gastrointestinal, respiratory, and genitourinary tracts. Counts of 0 to 450 eosinophils per cubic millimeter of blood are considered within normal limits.
  • Eosinophilic disorders occur when eosinophils are found in above-normal amounts in various parts of the body and/or when there is a higher than normal ratio of hypodense versus normodense esosinophils (e.g., greater than 30%).
  • the eosinophilic disorder described herein are characterized by an overabundance of eosinophils (eosinophilia). The increased number of eosinophils inflame tissues and cause organ damage. The heart, lungs, skin, and nervous system are most often affected, but any organ can be damaged.
  • Eosinophilic disorders are diagnosed according to the location where the levels of eosinophils are elevated:
  • Eosinophilic esophagitis esophagus - EoE
  • Hypereosinophilic syndrome blood and any organ - HES
  • diseases and disorders in which eosinophils play a role are: asthma, immunoglobulin (IgE)-mediated food allergy, eosinophilic esophagitis (inflammation of the esophagus), inflammatory bowel disease, COPD, allergic colitis, astro-esophageal reflux, eosinophilic gastrointestinal disease (EGID), eosinophilic gastroenteritis, endomyocardial fibrosis, Loeffler's endocarditis.
  • IgE immunoglobulin
  • IgE immunoglobulin
  • eosinophilic esophagitis inflammation of the esophagus
  • COPD allergic colitis
  • astro-esophageal reflux eosinophilic gastrointestinal disease
  • EGID eosinophilic gastroenteritis
  • endomyocardial fibrosis Loe
  • Davies disease episodic angioedema associated with eosinophilia, eosinophilia-myalgia syndrome/Spanish toxic oil syndrome, liver cirrhosis, dermatitis herpetiformis, Bullous pemphigoid, Churg-Strauss syndrome, acute myelogenous eosinophilic leukemia, acute lymphocytic eosinophilic leukemia, systemic mastocytosis with eosinophilia, allergic rhinitis, eczema, Wegener's granulomatosis, polyarteritis nodosa, eosinophilic fasciitis, and rheumatoid arthritis.
  • one aspect of the present disclosure is a method of treating an eosinophilic disorder, comprising administering to the subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
  • the eosinophilic disorder is selected from hypereosinophilic syndrome, eosinophilia, eosinophilic enterogastritis, eosinophilic leukemia, eosinophilic granuloma and Kimura's disease.
  • the eosinophilic disorder is hypereosinophilic syndrome. In a specific embodiment, the hypereosinophilic syndrome is idiopathic hypereosinophilic syndrome. In one embodiment, the eosinophilic disorder is eosinophilic leukemia. In a specific embodiment, the eosinophilic leukemia is chronic eosinophilic leukemia. In another embodiment, the eosinophilic disorder is refractory to treatment with imatinib, sunitinib, and/or regorafenib. In a specific embodiment, the eosinophilic disorder is refractory to treatment with imatinib.
  • Another aspect of the present disclosure is a method of reducing the number of eosinophils in a subject in need thereof comprising administering to the subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.
  • the disclosed methods reduce the number of eosinophils in the blood, bone marrow, gastrointestinal tract (e.g ., esophagus, stomach, small intestine and colon), or lung.
  • a method disclosed herein reduces the number of blood eosinophils.
  • a method disclosed herein reduces the number of lung eosinophils.
  • a method disclosed herein reduces the number of eosinophil precursor cells.
  • the disclosed methods reduce (post-administration) the number of eosinophils by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% ; at least about 90%, at least about 95% or at least about 99%.
  • a method disclosed herein reduces the number of eosinophils below the limit of detection.
  • the disclosed methods reduce (post-administration) the number of eosinophil precursors by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99%.
  • a method disclosed herein reduces the number of eosinophil precursors below the limit of detection.
  • the disclosed methods reduce eosinophils to a level below detection following a single administration of Compound (I) or a pharmaceutically acceptable salt thereof.
  • a single administration of Compound (I) or a pharmaceutically acceptable salt thereof reduces eosinophils to a level below detection for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 2 weeks, at least about
  • the disclosed methods reduce eosinophil precursors following a single administration of Compound (I) or a pharmaceutically acceptable salt thereof.
  • a single administration of Compound (I) or a pharmaceutically acceptable salt thereof reduces eosinophil precursors to a level below detection for at least about 1 day, at least about 2 days, at least about 3 days, at least about
  • the disclosure provides a method of treating an eosinophilic disorder, comprising administering to a subject in need thereof an amount of 30 mg to 400 mg (e.g ., 100 mg to 300 mg, or 200 mg to 300 mg) of Compound (I) and/or a pharmaceutically acceptable salt thereof once a day.
  • the amount is 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg once a day.
  • the amount is 25 mg once a day. In some embodiments, the amount is 50 mg once a day. In some embodiments, the amount is 75 mg once a day. In some embodiments, the amount is 100 mg once a day. In some embodiments, the amount is 150 mg once a day. In some embodiments, the amount is 200 mg once a day.
  • the amount is 250 mg once a day. In some embodiments, the amount is 300 mg once a day.
  • Compound (I) refers to a compound having a chemical name (S)-l- (4-fluorophenyl)- 1 -(2-(4-(6-( 1 -methyl- 1 H-pyrazol-4-yl)pyrrolo[2, 1-f] [1 ,2,4] triazin-4- yl)piperazin-yl)pyrimidin-5-yl)ethan-l-amine, which has the following structure:
  • Compound (I) is disclosed in WO 2015/057873, the entire teachings of which are incorporated herein by reference. The preparation of Compound (I) is described in Example 7 of WO 2015/057873.
  • Compound (I) was developed to selectively target KIT D816V and other KIT exon 17 mutations, and has demonstrated potent and selective activity against KIT D816V in vitro , robust growth inhibition in a tyrosine kinase inhibitor (TKI)-resistant mastocytoma model in vivo , and tolerability at active doses in toxicology and safety pharmacology studies.
  • TKI tyrosine kinase inhibitor
  • An ongoing Phase 1 study of Compound (I) in patients with advanced systemic mastocytosis (AdvSM) (NCT02561988) is evaluating safety and preliminary efficacy.
  • the recommended Phase 2 dose was identified as 300 mg once a day (QD), and an expansion cohort of the study is further evaluating efficacy and safety of this dose in a larger cohort of patients, as well as validating the AdvSM Symptom Assessment Form (AdvSM-SAF) that has been developed to assess the impact of Compound (I) on symptom improvement in patients with AdvSM. Based on emerging safety and efficacy data in patients treated at 300 mg QD, an additional cohort of patients treated at 200 mg QD was added.
  • AdvSM-SAF AdvSM Symptom Assessment Form
  • Activating mutations at the D816 position are found in eosinophilic disorders, with the most common mutations being D816V and D816Y.
  • the D816V mutation is found in the activation loop of the kinase domain and leads to constitutive activation of KIT kinase.
  • imatinib Primary treatment with a KIT inhibitor such as imatinib has also been shown to be beneficial for initial treatment of eosinophilic disorders.
  • imatinib is approved for the treatment of idocratic hypereosinophilic syndrome.
  • resistance to imatinib occurs within months through somatic mutation.
  • These secondary imatinib resistant mutations are most frequently located on Exon 11, 13, 14, 17 or 18.
  • Compound (I) or a pharmaceutically acceptable salt thereof can be active against one or more KIT mutations in Exon 17 (e.g ., D816V, D816Y, D816F, D816K, D816H, D816A, D816G, D820A, D820E, D820G, N822K, N822H, Y823D, and A829P), and much less active against wild-type KIT.
  • KIT mutations in Exon 17 e.g ., D816V, D816Y, D816F, D816K, D816H, D816A, D816G, D820A, D820E, D820G, N822K, N822H, Y823D, and A829P
  • Compound (I) or a pharmaceutically acceptable salt thereof can be active against a D816 mutation in KIT in Exon 17.
  • the D816 mutation is D816V.
  • the D816 mutation is D816Y.
  • the term “pharmaceutically acceptable salt” refers to a non-toxic salt form of a compound of this disclosure.
  • Pharmaceutically acceptable salts of Compound (I) include those derived from suitable inorganic and organic acids and bases. Pharmaceutically acceptable salts are well known in the art. Suitable pharmaceutically acceptable salts are, e.g., those disclosed in Berge, S.M., et al. J. Pharma. Sci. 66:1-19 (1977).
  • Non-limiting examples of pharmaceutically acceptable salts disclosed in that article include: acetate; benzenesulfonate; benzoate; bicarbonate; bitartrate; bromide; calcium edetate; camsylate; carbonate; chloride; citrate; dihydrochloride; edetate; edisylate; estolate; esylate; fumarate; gluceptate; gluconate; glutamate; glycollylarsanilate; hexylresorcinate; hydrabamine; hydrobromide; hydrochloride; hydroxynaphthoate; iodide; isethionate; lactate; lactobionate; malate; maleate; mandelate; mesylate; methylbromide; methylnitrate; methylsulfate; mucate; napsylate; nitrate; pamoate (embonate); pantothenate; phosphate/diphosphate; polygalactur
  • Non-limiting examples of pharmaceutically acceptable salts derived from appropriate acids include: salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, or perchloric acid; salts formed with organic acids, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid; and salts formed by using other methods used in the art, such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, or perchloric acid
  • salts formed with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid
  • salts formed by using other methods used in the art such as ion exchange.
  • compositions include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate,
  • Non-limiting examples of pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium, and N+(Cl-4 alkyl)4 salts. This disclosure also envisions the quatemization of any basic nitrogen-containing groups of the compounds disclosed herein.
  • Non-limiting examples of alkali and alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium.
  • Further non-limiting examples of pharmaceutically acceptable salts include ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
  • Other non-limiting examples of pharmaceutically acceptable salts include besylate and glucosamine salts.
  • a therapeutically effective amount of a compound disclosed herein refers to an amount of the compound that will elicit a biological or medical response in a subject, e.g., reduce or inhibit enzyme or protein activity, ameliorate symptoms, alleviate conditions, or slow or delay disease progression.
  • the term “patient” or “subject” refers to an organism to be treated by the methods of the disclosure.
  • Non-limiting example organisms include mammals, e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like.
  • the organism is a human.
  • the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition includes any effect, e.g., lessening, reducing, modulating, ameliorating, and/or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the severity of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.
  • Hypereosinophilic syndrome is a group of blood disorders that are characterized by high numbers of eosinophils — white blood cells that play an important role in immune system. Over time, the excess eosinophils enter various tissues, eventually damaging organs.
  • the contemporary classification of HES includes (1) idiopathic HES in which the cause of HE remains unknown, (2) primary (neoplastic) HES in which eosinophils are found to be clonal, and (3) secondary (reactive) HES with the presence of cytokine-driven non- clonal HE.
  • a unique form of secondary HES is called lymphocytic in which aberrant T-cells can be identified in blood.
  • Compound (I) and/or pharmaceutically acceptable salts thereof described herein are useful as an active pharmaceutical ingredients (API) as well as materials for preparing pharmaceutical compositions that incorporate one or more pharmaceutically acceptable excipients and is suitable for administration to human subjects.
  • the disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof and at least one additional pharmaceutically acceptable excipient.
  • pharmaceutically acceptable excipient refers to a pharmaceutically acceptable material, composition, and/or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each excipient must be “pharmaceutically acceptable” in the sense of being compatible with the subject composition and its components and not injurious to the patient.
  • materials which may serve as pharmaceutically acceptable excipients include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth;
  • oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil;
  • glycols such as propylene glycol;
  • polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol;
  • esters such as ethyl oleate and ethyl laurate;
  • compositions disclosed herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
  • parenteral includes subcutaneous, intravenous, intramuscular, intra- articular, intra- synovial, intrastemal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques.
  • the compositions of the disclosure are administered orally, intraperitoneally, or intravenously.
  • Sterile injectable forms of the pharmaceutical compositions of this disclosure may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • a non-toxic parenterally acceptable diluent or solvent for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tween, Spans, and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions disclosed herein may also be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions, or solutions.
  • aqueous suspensions are required for oral use, the active ingredient is typically combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents may also be added.
  • the pharmaceutical composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof is a tablet prepared using methods known in the art.
  • the tablet is an immediate release tablet for oral administration.
  • Compound (I) and/or a pharmaceutically acceptable salt thereof is blended with pharmacopeial excipients to form an immediate release tablet.
  • the excipients comprising the tablet are microcrystalline cellulose, copovidone, croscarmellose sodium, and magnesium sterate.
  • the formulation blend is roller compacted, compressed into round tablets, and aesthetically film coated.
  • Part 1 dose-escalation
  • Part 2 expansion
  • Systemic mastocytosis diagnosis confirmation for study eligibility is to be assessed using the WHO criteria for diagnosis and subclassification.
  • Evaluable C-findings per modified IWG-MRT-ECNM criteria are to be used to assess response.
  • a treatment cycle is 28 days in duration.
  • ECG electrocardiogram
  • PGIS patient general impression of symptom severity
  • EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire
  • Advanced SM response were assessed by imaging (magnetic resonance imaging [MRI] or computed tomography [CT]) and bone marrow (BM) evaluation at C3D1, C5D1 (imaging only), C7D1, C11D1, and C18D1. After Cl 8, AdvSM response were assessed every 6 cycles.
  • imaging magnetic resonance imaging [MRI] or computed tomography [CT]
  • CT computed tomography
  • BM bone marrow
  • EOT end of treatment
  • Compound (I) 200 mg QD were selected as the starting dose for the remainder of the study; all patients newly enrolled into Part 2 of the study received 200 mg as their starting dose.
  • Eosinophils in patients were measured at C1D15 (cycle 1, day 15) via a routine blood test, see , e.g., LaGow B et al., eds. PDR Lab Advisor. A Comprehensive Point-of-Care Guide for Over 600 Lab Tests. 1 st ed. Montvale, NJ: Thomson PDR, 2007; Pagana K, Pagana TJ eds. Mosby's Manual of Diagnostic and Laboratory Tests. 5 th Ed. St. Louis, Missouri. 2014; https://www.ebmconsult.com/articles/lah-test-eosinophiI-count and https://www.cancer.net/cancer-types/leukemia-eosinophilic/diagnosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2020/054221 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib Ceased WO2021067917A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP20797912.1A EP4041244B1 (en) 2019-10-04 2020-10-05 Avapritinib for use in the treatment of eosinophilic disorders
JP2022520638A JP2022551105A (ja) 2019-10-04 2020-10-05 アバプリチニブでの好酸球性障害の治療
CN202080081643.7A CN114746096A (zh) 2019-10-04 2020-10-05 使用阿伐替尼治疗嗜酸性粒细胞紊乱
US17/766,200 US20240075041A1 (en) 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib
JP2025135336A JP2025169361A (ja) 2019-10-04 2025-08-15 アバプリチニブでの好酸球性障害の治療

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910931P 2019-10-04 2019-10-04
US62/910,931 2019-10-04

Publications (1)

Publication Number Publication Date
WO2021067917A1 true WO2021067917A1 (en) 2021-04-08

Family

ID=73030210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/054221 Ceased WO2021067917A1 (en) 2019-10-04 2020-10-05 Treatment of eosinophilic disorders with avapritinib

Country Status (6)

Country Link
US (1) US20240075041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041244B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022551105A (cg-RX-API-DMAC7.html)
CN (1) CN114746096A (cg-RX-API-DMAC7.html)
TW (1) TW202126306A (cg-RX-API-DMAC7.html)
WO (1) WO2021067917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117185A1 (en) * 2005-05-02 2006-11-09 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
WO2013059631A1 (en) * 2011-10-21 2013-04-25 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
WO2015057873A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CN109970745A (zh) * 2018-04-16 2019-07-05 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
KR101652229B1 (ko) * 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117185A1 (en) * 2005-05-02 2006-11-09 Novartis Ag Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
WO2013059631A1 (en) * 2011-10-21 2013-04-25 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4] oxazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl] 2,4-pyrimidinediamine
WO2015057873A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
CN109970745A (zh) * 2018-04-16 2019-07-05 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEKKER
"Mosby's Manual of Diagnostic and Laboratory Tests", 2014
"PDR Lab Advisor. A Comprehensive Point-of-Care Guide for Over 600 Lab Tests", 2007, THOMSON PDR
ADV. IMMUNOL., vol. 39, 1986, pages 177
AM. J. CARDIOL., vol. 52, 1983, pages 321
AM. REV. RESPIR. DIS, vol. 132, 1985, pages 981
ANN. INTERN. MED., vol. 97, 1982, pages 78
BERGE, S.M. ET AL., J. PHARMA. SCI., vol. 66, 1977, pages 1 - 19
CLIN. EXP. IMMUNOL., vol. 24, 1976, pages 423
CLIN. EXP. IMMUNOL., vol. 85, 1991, pages 312
IMMUNOL. TODAY, vol. 13, 1992, pages 501
IMMUNOLOGY, vol. 47, 1982, pages 531
J. EXP. MED., vol. 172, 1990, pages 1347
J. IMMUNOL., vol. 142, 1989, pages 4416
JASON G. KETTLE ET AL: "Discovery of N -(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H -1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 19, 11 September 2018 (2018-09-11), pages 8797 - 8810, XP055756283, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b00938 *
MICHAEL E. WECHSLER ET AL: "Novel targeted therapies for eosinophilic disorders", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 130, no. 3, 1 September 2012 (2012-09-01), AMSTERDAM, NL, pages 563 - 571, XP055756420, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2012.07.027 *
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
VENKATESH PILLA REDDY ET AL: "The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST", CLINICAL CANCER RESEARCH, vol. 26, no. 14, 15 July 2020 (2020-07-15), US, pages 3751 - 3759, XP055756234, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-19-2848 *

Also Published As

Publication number Publication date
JP2022551105A (ja) 2022-12-07
EP4041244B1 (en) 2026-07-15
EP4041244A1 (en) 2022-08-17
JP2025169361A (ja) 2025-11-12
TW202126306A (zh) 2021-07-16
US20240075041A1 (en) 2024-03-07
CN114746096A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
JP2020196750A (ja) 線維症を処置するためのセニクリビロック併用療法
US12257237B2 (en) Tinostamustine for use in treating sarcoma
JP2015511632A (ja) メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
US20230330106A1 (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
CA2914310A1 (en) Pharmaceutical combinations
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
EP3256124B1 (en) Composition comprising cenicriviroc and fumaric acid for use in the treatment of acute liver injury or peritonitis
WO2021229439A1 (en) Therapeutic combinations comprising a craf inhibitor
JP2025169361A (ja) アバプリチニブでの好酸球性障害の治療
CN117982507A (zh) 英菲格拉替尼在治疗胃癌和腺癌中的用途
CN113811296A (zh) 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法
WO2021091846A1 (en) Treatment of mast cell diseases and eosinophilic disorders
JP2017527627A (ja) 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ
CN106061505A (zh) 用于治疗癌症的含pi3k抑制剂的药物组合
CN111343983A (zh) 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
JP2024518426A (ja) 投与レジメン
KR20230061527A (ko) 염증성 장 질환을 치료하는 방법
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
JP2026516050A (ja) 多発性硬化症を治療するためのbtk阻害剤
CN121969369A (zh) Parp-1选择性抑制剂和替莫唑胺的组合及其治疗神经胶质瘤的用途
HK40079704A (en) Treatment of mast cell diseases and eosinophilic disorders
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
HK40029681A (en) Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20797912

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 17766200

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2022520638

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020797912

Country of ref document: EP

Effective date: 20220504

WWG Wipo information: grant in national office

Ref document number: 2020797912

Country of ref document: EP